Edwards Lifesciences Corp (NYSE:EW) VP Catherine M. Szyman sold 1,116 shares of the company’s stock in a transaction dated Monday, March 23rd. The shares were sold at an average price of $162.95, for a total value of $181,852.20. Following the sale, the vice president now owns 15,773 shares in the company, valued at $2,570,210.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Shares of NYSE EW opened at $190.93 on Thursday. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.31 and a quick ratio of 2.60. The stock has a market capitalization of $32.88 billion, a P/E ratio of 38.65, a price-to-earnings-growth ratio of 1.56 and a beta of 0.80. Edwards Lifesciences Corp has a 1-year low of $154.52 and a 1-year high of $247.64. The business has a fifty day moving average price of $209.11 and a 200 day moving average price of $226.01.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, January 30th. The medical research company reported $1.46 earnings per share for the quarter, missing analysts’ consensus estimates of $1.49 by ($0.03). Edwards Lifesciences had a return on equity of 31.73% and a net margin of 24.08%. The company had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. During the same quarter last year, the company earned $1.17 earnings per share. The company’s revenue for the quarter was up 20.1% compared to the same quarter last year. As a group, equities research analysts anticipate that Edwards Lifesciences Corp will post 6.26 earnings per share for the current fiscal year.
Several research analysts recently weighed in on the stock. Jefferies Financial Group upped their price objective on shares of Edwards Lifesciences from $255.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, December 3rd. Morgan Stanley upped their price objective on shares of Edwards Lifesciences from $248.00 to $270.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. BTIG Research assumed coverage on shares of Edwards Lifesciences in a research report on Thursday, February 6th. They issued a “hold” rating on the stock. Credit Suisse Group decreased their price objective on shares of Edwards Lifesciences from $278.00 to $267.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. Finally, Wells Fargo & Co upped their price objective on shares of Edwards Lifesciences from $270.00 to $272.00 and gave the stock an “overweight” rating in a research report on Friday, January 31st. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and sixteen have assigned a buy rating to the company’s stock. Edwards Lifesciences currently has a consensus rating of “Buy” and a consensus price target of $252.95.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
See Also: Dead Cat Bounce
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.